Literature DB >> 7508746

Catalytically distinct conformations of the ribonuclease H of HIV-1 reverse transcriptase by substrate cleavage patterns and inhibition by azidothymidylate and N-ethylmaleimide.

X Zhan1, C K Tan, W A Scott, A M Mian, K M Downey, A G So.   

Abstract

The RNase H activity of recombinant HIV-1 reverse transcriptase (RT) has been characterized with respect to inhibition by azidothymidylate (AZTMP) and N-ethylmaleimide (NEM) and to cleavage patterns using either poly(rA)/poly(dT) or poly(rG)/poly(dC) as model substrate and either Mg2+ or Mn2+ as divalent cation activator. The inhibitory potency of AZTMP and other nucleotide analogues was found to be dependent on both the composition of the substrate and the divalent cation. The enzyme was significantly more sensitive to AZTMP inhibition with poly(rG)/poly(dC) than with poly(rA)/poly(dT) as substrate and in Mn2+ than in Mg2+ with either substrate. Kinetic studies indicated that AZTMP is a competitive inhibitor with respect to the substrate in Mn2+ whereas it behaves as an uncompetitive inhibitor in Mg2+. These results suggest that the enzyme may exist in two distinct forms depending on whether Mg2+ or Mn2+ is the divalent cation activator. Consistent with this suggestion is the alteration in the mode of cleavage of the substrate upon substitution of Mg2+ with Mn2+. In Mg2+, hydrolysis of poly(rA)/poly(dT) appears to be solely endonucleolytic, whereas in Mn2+, hydrolysis is both endonucleolytic and exonucleolytic. With poly(rG)/poly(dC) as substrate, hydrolysis is both endonucleolytic and exonucleolytic in either Mg2+ or Mn2+. There is a positive correlation between sensitivity to AZTMP and production of mononucleotides, suggesting that the exonuclease activity of RNase H is preferentially inhibited by AZTMP. The sensitivity of RNase H to inhibition by N-ethylmaleimide was also found to be markedly influenced by the substrate composition and the divalent cation activator, being most sensitive under conditions in which endonucleolytic activity predominates.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508746     DOI: 10.1021/bi00172a012

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

Review 1.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

3.  The amphiphilic properties of novenamines determine their activity as inhibitors of HIV-1 RNase H.

Authors:  I W Althaus; K M Franks; K B Langley; F J Kézdy; T Peterson; S E Buxser; D E Decker; L A Dolak; R G Ulrich; F Reusser
Journal:  Experientia       Date:  1996-04-15

4.  Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies.

Authors:  Anthony K Felts; Krystal Labarge; Joseph D Bauman; Dishaben V Patel; Daniel M Himmel; Eddy Arnold; Michael A Parniak; Ronald M Levy
Journal:  J Chem Inf Model       Date:  2011-07-26       Impact factor: 4.956

5.  Comparison of second-strand transfer requirements and RNase H cleavages catalyzed by human immunodeficiency virus type 1 reverse transcriptase (RT) and E478Q RT.

Authors:  C S Snyder; M J Roth
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism.

Authors:  P R Meyer; S E Matsuura; A G So; W A Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

7.  Specific initiation and switch to elongation of human immunodeficiency virus type 1 reverse transcription require the post-transcriptional modifications of primer tRNA3Lys.

Authors:  C Isel; J M Lanchy; S F Le Grice; C Ehresmann; B Ehresmann; R Marquet
Journal:  EMBO J       Date:  1996-02-15       Impact factor: 11.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.